The American College of Cardiology/American Heart Association Task Force on Clinical Data Standards published a report June 23 listing and defining key data elements related to cardiovascular and noncardiovascular complications of COVID-19.
Instead of sitting for the traditional 10-year MOC exam, LKA participants choose when and where to answer assessment questions, find out in real-time if they were right or wrong, and receive a rationale and references to provide context and enhance learning.
The world of advanced heart failure is relatively small and specialized, but the most important thing learners should know is when to identify a patient who's heading down that slippery slope of advanced heart failure.
Dr. Bakris has been extensively involved as either a principal investigator or on the steering committees of national and international trials involving diabetic kidney disease progression and resistant hypertension. There are many people with different types of hypertension, isolated, systolic, masked, and white coat hypertension. Continue reading...
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
Dr. Neil Stone serves as faculty for K2P’s LEGENDS series, where he has provided a talk on the prevention of cardiovascular disease through lipid management.
Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
Dr. Hugh Calkins is a member of the K2P Legends Series faculty and has provided a video entitled “Electrophysiology: State of the Science.”
Dr. Deepak Bhatt serves as faculty for K2P’s LEGENDS series, where he has provided a retrospective on coronary artery disease. He also contributes regularly to other K2P activities, providing education and an expert perspective to many of our programs.
Dr. Ty Gluckman is the Curriculum Chair for K2P’s CurrentMD™ Cardiology product, where he helps to strategize and oversee the cardiology curriculum. He also contributes regular content on a variety of topics, including evaluation of chest pain and risk factor assessment.
The American College of Cardiology has released a new Expert Consensus Decision Pathway (ECDP) to address the evaluation and management of some of the more common post-COVID cardiovascular consequences. The effort was co-chaired by Ty Gluckman, MD, MHA, FACC, and Nicole M. Bhave, MD, FACC.
FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.